Relugolix APIs are part of Loncom Pharma's reproductive health category, designed to provide a gonadotropin-releasing hormone antagonist for treating conditions like prostate cancer and uterine fibroids, demonstrating the company's commitment to innovative hormonal therapies.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
